About this Research Topic

Background

Immune checkpoints orchestrate a complex regulatory network, tasked with keeping the immune system in check to avoid autoimmune and inflammatory disease. The field is dominated by development of new checkpoint blockers to treat cancer and infectious diseases, following the success of antibody therapies targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) that have revolutionized cancer treatment. Regulatory T cells (Tregs) and members of a family of intracellular regulators called suppressors of cytokine signaling (CIS, SOCS1, SOCS2 and SOCS3) are also central to limiting the immune response. SOCS1 is a key checkpoint in the immune response to cancer and infection, SOCS3 in various inflammatory diseases, and together they allow crosstalk between cytokines in non-immune and immune cells. CIS (CISH gene) is a critical checkpoint in natural killer (NK) and T cell control of cancer, while SOCS2 has been reported to have roles in controlling allergy and cancer, including acute myeloid leukemia. Many of these regulatory players are interconnected and interdependent. In fact, SOCS1 was shown to stabilize Foxp3+ Treg peripheral cells. There is also evidence that SOCS1 can regulate other checkpoint players such as PD-1, via inhibition of interferon signaling. Thus, manipulation of SOCS activity or levels could influence other checkpoint factors.

Given that the SOCS proteins are intracellular checkpoint regulators, the challenge is to positively and negatively regulate these molecules in an informative way with potential for therapeutic translation. In this regard, a peptide mimetic of the key SOCS1 kinase inhibitory region (KIR) referred to as “SOCS1-KIR,” binds to the catalytic site of Janus kinases JAK2 and TYK2 and thus blocks both type II and type I interferon (IFN) signaling. In addition, SOCS1-KIR can bind to the MyD88 associated adaptor protein (MAL) and regulate signaling emanating through toll like receptors 2 and 4 (TLR2 and 4). When palmitated or polycationated by polyarginines, or encapsulated in hydrogels, SOCS1-KIR can penetrate the cell membrane and is an effective therapy in models of multiple sclerosis and lupus. By contrast, a peptide corresponding to the JAK2 activation loop blocks SOCS1/3 activity and enhances the immune response against a broad range of viral infections, including SARS-CoV-2; and has potent anti-melanoma activity in an aggressive mouse melanoma model. SOCS3 is associated with several metabolic disorders, most significantly the inhibition of insulin and leptin signaling in obesity and type 2 diabetes.

Despite several fundamental publications, there appears to be a lack of awareness that the SOCS are key immune checkpoints. This was reflected in a recent call for innovative immune checkpoint inhibitors, which neglected to mention the SOCS system. This may be because unlike PD-1 and CTLA-4 which can be targeted by antibodies, regulation of SOCS activity presents a unique challenge due to their intracellular location, and the inherent difficulty of targeting the conserved SH2 or SOCS box function. Contrary to this perception, there are multiple strategies, including gene editing, anti-sense oligonucleotides, microRNAs and intracellular antibodies, that could be used to manipulate SOCS function. The recent development of a chemical SOCS2-SH2 inhibitor also offers hope that this domain is not as intractable as previously thought. Notably, effective peptidomimetic agonists and antagonists, as indicated above, have been developed with potential for treatment of viral and bacterial infections, cancer, autoimmune and inflammatory diseases, as well as the cellular dysregulation associated with type 2 diabetes. This Research Topic aims to explore these various SOCS related disorders and present an approach to their amelioration. We believe the controlled modulation of certain SOCS proteins to dampen or enhance immune and non-immune functions will provide a needed innovation in the immune checkpoint field.

We are interested in Original Research, Review, and Perspective articles, focusing on but not limited to the following areas:
1. SOCS as checkpoint modulators. This is not obvious based on the current literature.
2. SOCS mimetics and antagonists as regulators of intracellular checkpoint activity. The intracellular nature of SOCS and the difficulty in assessing in the context of therapeutics probably plays a role in “ignoring” SOCS in checkpoint inhibitions.
3. SOCS role in autoimmune and inflammatory disorders. There are ample examples of SOCS playing a role in lupus, multiple sclerosis, inflammatory eye disorders, arthritis, etc.
4. Role of SOCS3 in insulin resistance and type 2 diabetes. SOCS3 plays a role in a major health issue but is little recognized for this.
5. Role of SOCS proteins in viral infections in general. There is a plethora of examples here with a variety of viruses including SARS-CoV-2.
6. Role of SOCS proteins in bacterial infections. There is evidence that SOCS may play a role in methicillin-resistant Staphylococcus aureus (MRSA) infections.
7. Role of SOCS in COVID-19 pandemic. This viral pandemic represents a special case in terms of a demonstrated SOCS connection.
8. Role of SOCS in cancer immunotherapy. PD-1 is highly cited as a checkpoint target but seems effective only in limited situations.
9. Crosstalk between SOCS and regulatory T cells (Tregs). Tregs are too important to ignore their checkpoint modulator interactions, including those involving SOCS.
10. SOCS modulation of the immune system with possible focus on specific areas such as natural killer (NK) cell activity. NK cell function has been extensively shown to be regulated by SOCS.



Professor Sandra Nicholson and Dr. Karen Doggett are employees of the Walter and Eliza Hall Institute, which receives milestone and royalty payments related to venetoclax; Professor Nicholson receives a share of these royalties from the Institute. The Walter and Eliza Hall Institute also receives milestone payments from ONK Therapeutics Ltd and Servier, an international pharmaceutical governed by non-profit, FIRS; Professor Nicholson receives benefits related to these payments. Professor Sandra Nicholson and Dr. Karen Doggett have received research funding from Servier. The other topic editors declare no competing interests with regard to the topic theme.

Keywords: Suppressors of cytokine signaling, SOCS, cancer immunotherapy, viral infections treatment, bacterial infections treatment, autoimmunity therapy, inflammatory disorders therapy, type 2 diabetes therapy, Autoimmune or endotoxin induced uveitis, COVID-19, NK cells, Tregs, immune checkpoint inhibitors

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Frequently asked questions

• What is a Research Topic?

  Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

  Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

• Why does Frontiers publish Research Topics? 

  The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

  Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

• Why are Research Topics important for journals?

  As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

  A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

• How do we ensure the quality of articles within Research Topics?

  Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

  In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

• What are the benefits of publishing my article in a Research Topic?

  Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

  As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

  Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

   
• What types of articles can be published in a Research Topic?

  Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

  Check available article types here 

• Can I suggest a new Research Topic? 

  Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

  Suggest your topic here 

• Who leads a Research Topic? 

  A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

  The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

• What is the role of a topic editor?

  As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

   

  You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

• What support will I receive when editing a new Research Topic? 

  As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

• As a junior researcher, can I be involved in editing a Research Topic? 

  If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

• Can I get a certificate for editing a Research Topic?

  Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

• Who will I collaborate with?

  Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

• How long does it take to publish a Research Topic?

  As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

  Find out more about our Research Topics

• What fee support is available to authors publishing in a Research Topic?

  Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

  Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

• Will there be a printed version of my Research Topic?

  In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.